目的 探讨卡瑞利珠单抗治疗中国转移性、复发性及晚期宫颈癌患者的疗效及安全性。方法 系统地检索PubMed、Embase、Cochrane Library、Web of Science、Wiley Online Library、中国学术期刊全文数据库（CNKI）、万方数据库（WanfangData）、维普生物医学数据库（VIP），筛选建库至2025年8月15日已发表的关于卡瑞利珠单抗治疗中国转移性、复发性及晚期宫颈癌患者的临床研究，使用Stata 16.0软件进行Meta分析，结局指标包括疗效指标、安全性指标和预后指标。结果 共纳入21项研究，包含982例接受卡瑞利珠单抗治疗的患者，Meta分析结果显示：客观缓解率（ORR）为68%[95%置信区间（CI） ＝56%～79%]，疾病控制率（DCR）为84%（95% CI＝79%～88%），治疗相关死亡率为0（95% CI＝0～2%），12个月总生存率为71%（95% CI＝59%～83%），12个月无进展生存率（PFS）为44%（95% CI＝33%～56%）。结论 卡瑞利珠单抗在治疗中国转移性、复发性及晚期宫颈癌患者中展现出良好的抗肿瘤活性，且具有可控的安全性，但受限于研究样本量，仍需要更多高质量的随机对照试验（RCT）予以验证。

Objective To investigate the efficacy and safety of camrelizumab in the treatment of Chinese patients with metastatic, recurrent, and advanced cervical cancer. Methods A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, Wiley Online Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP databases for clinical studies published from inception until August 15, 2025, on camrelizumab treatment for Chinese patients with metastatic, recurrent, or advanced cervical cancer. Meta-analysis was performed using Stata 16.0 software. Outcome measures included efficacy indicators, safety indicators, and prognostic indicators. Results A total of 21 studies involving 982 patients treated with camrelizumab were included. The Meta-analysis results showed: The objective response rate (ORR) was 68% (95% CI = 56%-79%), the disease control rate (DCR) was 84% (95% CI = 79%-88%), the treatment-related mortality rate was 0 (95% CI = 0-2%), the 12-month overall survival (OS) rate was 71% (95% CI = 59%-83%), and the 12-month progression-free survival (PFS) rate was 44% (95% CI = 33%-56%). Conclusion Camrelizumab demonstrates promising antitumor activity and a manageable safety profile in the treatment of Chinese patients with metastatic, recurrent, and advanced cervical cancer. However, due to limitations in sample size across the included studies, further validation through more high-quality randomized controlled trials (RCTs) is warranted.

R737.33

福建省自然科学基金项目（2023J01825）